"3"^^ . . "Votava, Martin" . "Kr\u0161iak, Miloslav" . "Nemoci spojen\u00E9 s patologickou \u00FAzkost\u00ED jsou jednou z nej\u010Dast\u011Bj\u0161\u00EDch poruch chov\u00E1n\u00ED. L\u00E1tky, kter\u00E9 se pou\u017E\u00EDvaj\u00ED k jej\u00EDmu l\u00E9\u010Den\u00ED, p\u0159edev\u0161\u00EDm ovliv\u0148uj\u00ED GABAergn\u00ED (benzodiazepiny) a serotonergn\u00ED (antidepresiva) syst\u00E9m. Tato pr\u00E1ce pod\u00E1v\u00E1 p\u0159ehled o hlavn\u00EDch mechanizmech p\u016Fsoben\u00ED st\u00E1vaj\u00EDc\u00EDch anxiolytik a d\u00E1le o dal\u0161\u00EDch mo\u017Enostech jeho ovlivn\u011Bn\u00ED. Sou\u010Dasn\u00E1 terapie p\u016Fsob\u00ED do zna\u010Dn\u00E9 m\u00EDry nespecificky, a proto se v\u00FDzkum soust\u0159ed\u00ED na ovlivn\u011Bn\u00ED dal\u0161\u00EDch receptorov\u00FDch syst\u00E9m\u016F. Mezi nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED pat\u0159\u00ED noradrenergn\u00ED syst\u00E9m, ovlivn\u011Bn\u00ED receptor\u016F pro kortikotropin-releasing faktor, neurokininov\u00FDch, cholecystokininov\u00FDch ei glutam\u00E1tov\u00FDch NMDA receptor\u016F." . "[BC2C1A192C3D]" . . "anxiolytics"@en . "Anxiety diseases are one of the most frequent psychic disorders. Drugs, which are currently used, act mainly on GABAergic (benzodiazepines) or serotonergic (antidepressants) systems. This review summarizes the main mechanisms of action of anxiolytics and shows other possible options of anxiety treatment. The current therapy of anxiety is non-specific and thus researchers are still finding other neuromediator systems to influence. The most promising systems in the development of new anxiolytics are noradrenergic system, corticotropin-releasing factor receptors, neurokinin, cholecystokinin or glutamatergic NMDA receptors."@en . . . . "Mechanismy \u00FA\u010Dinku anxiolytik"@cs . . . "Mechanisms of action of anxiolytics"@en . "3" . . "CZ - \u010Cesk\u00E1 republika" . . . . "Mechanismy \u00FA\u010Dinku anxiolytik" . "Mechanisms of action of anxiolytics"@en . "6" . . "Psychiatrie pro praxi" . . "11120" . "Mechanismy \u00FA\u010Dinku anxiolytik"@cs . "529361" . . "Mechanismy \u00FA\u010Dinku anxiolytik" . "1213-0508" . "RIV/00216208:11120/05:00009572" . . "RIV/00216208:11120/05:00009572!RIV06-GA0-11120___" . . "Agov\u00E1, Viktoria" . "P(GP305/05/P003), Z(MSM0021620816)" . "3"^^ . . "73;75" . "Nemoci spojen\u00E9 s patologickou \u00FAzkost\u00ED jsou jednou z nej\u010Dast\u011Bj\u0161\u00EDch poruch chov\u00E1n\u00ED. L\u00E1tky, kter\u00E9 se pou\u017E\u00EDvaj\u00ED k jej\u00EDmu l\u00E9\u010Den\u00ED, p\u0159edev\u0161\u00EDm ovliv\u0148uj\u00ED GABAergn\u00ED (benzodiazepiny) a serotonergn\u00ED (antidepresiva) syst\u00E9m. Tato pr\u00E1ce pod\u00E1v\u00E1 p\u0159ehled o hlavn\u00EDch mechanizmech p\u016Fsoben\u00ED st\u00E1vaj\u00EDc\u00EDch anxiolytik a d\u00E1le o dal\u0161\u00EDch mo\u017Enostech jeho ovlivn\u011Bn\u00ED. Sou\u010Dasn\u00E1 terapie p\u016Fsob\u00ED do zna\u010Dn\u00E9 m\u00EDry nespecificky, a proto se v\u00FDzkum soust\u0159ed\u00ED na ovlivn\u011Bn\u00ED dal\u0161\u00EDch receptorov\u00FDch syst\u00E9m\u016F. Mezi nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED pat\u0159\u00ED noradrenergn\u00ED syst\u00E9m, ovlivn\u011Bn\u00ED receptor\u016F pro kortikotropin-releasing faktor, neurokininov\u00FDch, cholecystokininov\u00FDch ei glutam\u00E1tov\u00FDch NMDA receptor\u016F."@cs . "3"^^ .